Cyproheptadine: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Expand stub to full MedTemplate parameter set |
MDElliottMD (talk | contribs) parser-claude: Cyproheptadine MedTemplate refill, Top 300 stub upgrade |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Cyproheptadine (hydrochloride) | ||
| brand | | brand = Periactin (US brand discontinued; generic widely available) | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:Antihistamines|First-generation antihistamine]], [[:Category:Serotonin antagonists|Serotonin 5-HT2 antagonist]], [[:Category:Orexigenics|Appetite-promoting medicine (orexigenic)]] | ||
| | | uses = <vote slug="allergic-conditions-use">Allergic conditions including urticaria and seasonal allergies (FDA)</vote>, <vote slug="serotonin-syndrome-antidote-use">Serotonin syndrome (off-label; the standard pharmacological antidote alongside supportive care and benzodiazepines)</vote>, <vote slug="appetite-stimulation-cachexia-use">Appetite stimulation in failure to thrive, cachexia, and anorexia (off-label, evidence-supported in pediatric and adult populations)</vote>, <vote slug="migraine-prophylaxis-pediatric-use">Pediatric migraine prophylaxis (off-label)</vote>, <vote slug="ssri-sexual-dysfunction-adjunct-use">SSRI-induced sexual dysfunction (off-label adjunct, modest evidence)</vote> | ||
| uses | | starting_dose = Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID | ||
| starting_dose | | preparations = Tablets 4 mg; oral syrup 2 mg/5 mL | ||
| preparations | | fda_max = 32 mg/day adult; weight-based pediatric ceiling | ||
| | | pill_id = | ||
| routes = Oral | |||
| | | onset = 30-60 minutes | ||
| | | duration = 6-8 hours | ||
| | | halflife = 8-16 hours<ref name="periactin-label">FDA Prescribing Information, Periactin (cyproheptadine hydrochloride), Merck/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/010407s058lbl.pdf</ref> | ||
| | | bioavailability = ~95% (oral)<ref name="periactin-label" /> | ||
| | | pregnancy = Limited human data; older agent with substantial use experience.{{citation needed}} | ||
| legal = [[USLegal:Prescription only|Rx-only]] in US | |||
| | | mechanism = <vote slug="cyproheptadine-mech-claim">First-generation H1 histamine receptor antagonist with substantial additional '''5-HT2A and 5-HT2C serotonin receptor antagonism'''. The 5-HT2A antagonism is the basis of its role as the first-line pharmacological antidote for serotonin syndrome; the 5-HT2C antagonism underlies the appetite stimulation effect (the same receptor mechanism that drives weight gain with mirtazapine and olanzapine).</vote> Anticholinergic and sedating, with the standard first-generation antihistamine Beers-list concerns in elderly patients<ref name="periactin-label" />. | ||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Antihistamines]] | [[Category:Antihistamines]] | ||
[[Category:Serotonin antagonists]] | |||
[[Category:Orexigenics]] | |||